3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Breast Neoplasms
9
Pain, Postoperative
7
Lung Neoplasms
4
Depression
4
Brain Neoplasms
4
Anxiety Disorders
4
Prostatic Neoplasms
3
Pain
3
Ovarian Neoplasms
3
Neoplasms
3
Colonic Neoplasms
3
Agnosia
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Fallopian Tube Neoplasms
2
Delirium
2
Colorectal Neoplasms
2
Warts
1
Uterine Cervical Neoplasms
1
Trauma, Nervous System
1
Thrombosis
1
Synovial Cyst
1
Stroke
1
Spondylosis
1
Spondylolisthesis
1
Spinal Stenosis
1
Sleep Initiation and Maintenance Disorders
1
Sigmoid Neoplasms
1
Sepsis
1
Interventions
Paclitaxel
8
Hyperthermic Intraperitoneal Chemotherapy
6
Mitomycin
5
Cisplatin
5
Fluorouracil
4
Bevacizumab
4
Oxaliplatin
3
Leucovorin
3
Doxorubicin
3
Cytoreduction Surgical Procedures
3
Carboplatin
3
Blood Specimen Collection
3
sodium thiosulfate
2
pembrolizumab
2
Standard of Care
2
Laparoscopy
2
soluble LAG-3 protein, human
1
relacorilant
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
avelumab
1
X-Rays
1
Topotecan
1
Taxes
1
Specimen Handling
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Saline Solution
×
1 year
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts